Oral anticoagulants represent the cornerstone of stroke prevention in non-valvular atrial fibrillation. Direct oral anticoagulants and vitamin K antagonists significantly lower thromboembolic risk in high-risk individuals. Nevertheless, approximately 1% to 2% of patients still experience an acute cerebral infarction each year despite therapeutic dosing. This challenging clinical dilemma is defined as a breakthrough ischemic stroke. When an acute vascular event happens during ongoing oral anticoagulation, physicians face significant diagnostic uncertainty regarding the true causative mechanisms. In addition, these events carry substantial clinical morbidity and a heightened risk of subsequent neurological decline. Clinicians must therefore look beyond simple cardioembolic pathways to determine whether competing vascular diseases, pharmacological interactions, or occult systemic pathologies triggered the thromboembolic failure.

Understanding Breakthrough Ischemic Stroke in Atrial Fibrillation

Atrial fibrillation remains the primary cause of cardioembolic stroke across global populations. Consequently, anticoagulant therapy serves as the first-line therapeutic shield against left atrial thrombus formation. However, clinicians increasingly encounter patients who present with acute focal neurological deficits while adhering faithfully to their prescribed medication. A breakthrough ischemic stroke occurs when therapeutic anticoagulation fails to prevent cerebral ischemia. In many instances, the event does not reflect true anticoagulant failure alone. Instead, multiple concurrent pathological factors often converge to provoke cerebral hypoperfusion or arterial occlusion.

Several potential mechanisms explain why an ischemic cerebral event arises despite ongoing therapy. First, non-cardioembolic vascular diseases, such as large-artery atherosclerosis and small vessel arteriopathy, can precipitate acute strokes independently of atrial fibrillation. Second, altered pharmacokinetics may lead to subtherapeutic plasma drug concentrations. This issue frequently stems from severe renal fluctuations, altered gastrointestinal absorption, or adverse drug interactions. Third, hypercoagulable states, such as active malignancy or antiphospholipid syndrome, can overcome standard anticoagulant levels. Therefore, identifying the exact mechanistic contributor is vital for preventing rapid disease recurrence.

Key Findings and Patient Characteristics from ASPERA-R

The ASPERA-R study provides critical real-world insight into the clinical profiles of patients who suffer cerebrovascular accidents during anticoagulation. This multicenter retrospective investigation evaluated 1,649 consecutive patients with documented atrial fibrillation who developed an acute ischemic cerebral event between 2020 and 2025. Importantly, the investigators verified ongoing anticoagulation through stringent criteria. Specifically, they confirmed that patients taking direct oral anticoagulants had received their last dose within 48 hours, while those taking vitamin K antagonists maintained therapeutic international normalized ratio levels.

The cohort demonstrated a median age of 80.4 years, and females comprised 52.2% of the study population. Direct oral anticoagulants represented the predominant therapeutic regimen, accounting for 77.3% of all cases. Remarkably, the researchers identified at least one plausible underlying cause in 43.9% of the study participants. Pharmacokinetic and pharmacodynamic drug interactions emerged as the most frequent culprit, detected in 28.4% of the cohort. Furthermore, competing stroke etiologies were present in 24.3% of cases, whereas active malignancy occurred in 4.4%. Consequently, these findings emphasize that nearly half of all breakthrough events involve clearly identifiable and potentially modifiable pathophysiological factors.

The Impact of Drug Interactions and Competing Pathologies

Drug interactions represent a major contributor to therapeutic failure among elderly patients with atrial fibrillation. Because older individuals frequently live with multiple chronic comorbidities, polypharmacy is exceptionally common. Direct oral anticoagulants depend extensively on P-glycoprotein transport mechanisms and cytochrome P450 enzymatic pathways for metabolism and clearance. Consequently, concurrent administration of strong enzyme inducers or competing transporters can markedly reduce circulating anticoagulant concentrations. Antiepileptic agents, certain antiarrhythmic drugs, and specific antimicrobial therapies frequently drive these complex pharmacokinetic disruptions.

In addition to pharmacological interactions, competing vascular etiologies play a prominent role in breakthrough events. Severe carotid stenosis, intracranial atherosclerotic disease, and lacunar microangiopathy frequently coexist with cardiac dysrhythmias. When these separate pathologies cause arterial occlusion, standard anticoagulation cannot provide complete vascular protection because platelet activation and local shear stress drive thrombus propagation. Moreover, systemic malignancy promotes an aggressive prothrombotic state through mucin secretion and tissue factor expression. Therefore, clinicians must routinely assess whether an apparent anticoagulant failure actually represents a distinct vascular or systemic pathology requiring targeted multimodal intervention.

Clinical Outcomes and Recurrence Risks at Ninety Days

The prognostic implications of identifying an underlying etiology in breakthrough events are clinically profound. In the ASPERA-R study, patients with at least one identifiable cause faced significantly worse short-term neurological outcomes. Specifically, adjusted Cox proportional hazards regression models revealed a more than twofold increase in the risk of recurrent ischemic stroke at ninety days (HR 2.04, 95% CI 1.18–3.53) compared to patients without an identifiable cause. This heightened recurrence underscores the aggressive nature of unresolved concurrent pathologies.

Interestingly, the investigators observed no significant differences between groups regarding other general secondary clinical endpoints. However, sophisticated inverse probability-weighted analyses highlighted an alarming cardiovascular risk linked to drug interactions. Patients exposed to interacting medications exhibited a more than threefold higher risk of acute myocardial infarction (HR 3.26, 95% CI 1.30–8.17). This striking finding suggests that interacting pharmaceutical agents not only compromise cerebral protection, but also destabilize coronary vascular beds. Consequently, systemic drug interactions generate widespread cardiovascular vulnerability, making immediate medication review a clinical priority.

Diagnostic Workup and Secondary Prevention Strategies

When a patient experiences an acute stroke during anticoagulant treatment, clinicians must initiate a structured diagnostic evaluation. First, physicians must confirm medication adherence and assess exact dosing intervals. Blood testing should evaluate renal and hepatic function, while international normalized ratio testing or direct factor Xa/thrombin assays can assess anticoagulant activity. Simultaneously, the medical team should perform a rigorous medication reconciliation to detect potential cytochrome P450 or P-glycoprotein interactions. Clinicians must promptly eliminate or substitute any compromising pharmacological agents.

Second, comprehensive vascular and cardiac imaging is essential to isolate competing mechanisms. High-resolution computed tomography angiography or magnetic resonance angiography must evaluate intra- and extracranial vessels for severe atherosclerotic plaques. Echocardiography helps exclude complex aortic atheromas, left ventricular thrombi, or patent foramen ovale. If active occult cancer or autoimmune hypercoagulability is suspected, age-appropriate cancer screenings and thrombophilia panels are warranted. Addressing these distinct pathologies directly—through carotid revascularization, strict glycemic control, or lipid-lowering therapies—optimizes secondary prevention far better than blind anticoagulant switching.

Clinical Implications for Multidisciplinary Patient Management

Managing breakthrough cerebrovascular disease demands close collaboration between neurologists, cardiologists, clinical pharmacists, and general physicians. Historically, clinicians often responded to anticoagulant failure by simply switching between anticoagulant classes or adding antiplatelet agents. However, emerging evidence indicates that adding antiplatelet agents without a clear indication increases major bleeding risks without reducing recurrence. Similarly, arbitrarily changing anticoagulant drugs fails to address unmanaged competing vascular etiologies or ongoing systemic interactions.

Instead, modern clinical practice demands an individualized, mechanistic strategy. If clinicians identify severe carotid disease, they should pursue appropriate surgical or endovascular interventions. If dangerous drug interactions exist, pharmacists and physicians must collaborate to select alternative medications with favorable metabolic profiles. Furthermore, for select patients with confirmed cardioembolic recurrence despite verified compliance and optimal pharmacokinetics, interventional options like left atrial appendage occlusion may provide therapeutic value. Ultimately, systematic etiology-directed care transforms acute crisis management into durable, personalized vascular protection.

Frequently Asked Questions

What defines a breakthrough ischemic stroke during anticoagulation?

A breakthrough ischemic stroke occurs when an acute ischemic cerebral infarction develops despite ongoing therapeutic oral anticoagulation. Clinicians verify this condition by confirming that direct oral anticoagulants were ingested within 48 hours or that vitamin K antagonist therapy maintained a therapeutic international normalized ratio before symptom onset.

Why are drug interactions dangerous for patients taking direct oral anticoagulants?

Direct oral anticoagulants rely on cytochrome P450 enzymes and P-glycoprotein transporters for systemic clearance. Concomitant medications that induce these pathways can drastically reduce plasma anticoagulant concentrations. Consequently, these interactions impair thromboembolic protection, significantly increasing the risk of recurrent ischemic strokes and acute myocardial infarctions.

How should clinicians approach secondary prevention after a breakthrough stroke?

Clinicians should execute a comprehensive diagnostic workup to identify competing etiologies, active malignancies, or drug interactions. Rather than empirically switching anticoagulants or adding antiplatelet drugs, clinicians should tailor secondary prevention by eliminating interacting medications, managing atherosclerotic vascular disease, and optimizing underlying cardiovascular risk factors.

Disclaimer: This content is for informational and educational purposes only. Refer to the latest local and national guidelines for clinical practice.

References

De Santis F et al. Decoding the causes of ischemic stroke despite ongoing oral anticoagulation and their clinical impact: the ASPERA-R study. J Neurol. 2026 Aug 17. doi: 10.1007/s00415-026-14039-x. PMID: 42604885.

Lun R et al. Investigation and management of breakthrough ischemic stroke in anticoagulated patients with atrial fibrillation. BMJ. 2026;390:e084905.

Maarse M et al. Management Options for Atrial Fibrillation Patients Experiencing Stroke Despite Anticoagulation. JACC Clin Electrophysiol. 2024;10(12):2450-2462.

Seiffge DJ et al. Ischemic Stroke in Patients Under Oral Anticoagulation: The Achilles Heel of Atrial Fibrillation Management. J Clin Med. 2025;14(8):2601.